Skye Bioscience, Inc. — Director's Dealing 2023

Aug 28, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2023-08-18

Reporting Person: Versant Ventures III, LLC (10% Owner)
Reporting Person: Versant Venture Capital III, L.P. (10% Owner)
Reporting Person: Versant Side Fund III, L.P. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	498978878	Indirect
Common Stock	2946924	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrant (Right to Buy)	$0.0206	2033-08-18	Common Stock (130043230)		Indirect
Warrant (Right to Buy)	$0.0206	2033-08-18	Common Stock (768124)		Indirect

Footnotes

F1: Securities are directly held by Versant Venture Capital III, L.P. ("Versant III"). Versant Ventures III, LLC ("Versant Ventures III") is the sole general partner of Versant III and may be deemed to share voting and dispositive power over the securities held by Versant III. Versant Ventures III disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein.

F2: Securities are directly held by Versant Side Fund III, L.P. ("Side Fund III"). Versant Ventures III is the sole general partner of Side Fund III and may be deemed to share voting and dispositive power over the securities held by Side Fund III. Versant Ventures III disclaims beneficial ownership of such securities, except to the extent of its pecuniary interest therein.